Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Advanced glycation end products (AGEs) are a group of compounds, which are formed by non-enzymatic reactions between carbonyl groups of reducing sugars and free amino groups of proteins, lipids or nucleic acids and can be obtained exogenously from diet or formed endogenously within the body. AGEs accumulate intracellularly and extracellularly in all tissues and body fluids and can cross-link with other proteins and thus affect their normal functions.
The global advanced glycation end products market is estimated to be valued at US$ 1,368.5 million in 2020 and is expected to exhibit a CAGR of 6.3% over the forecast period (2020-2027).
Figure 1. Global Advanced Glycation End Products Market Share (%), By Region, 2019
Increasing cases of cancer is expected to propel the market growth over the forecast period
The increasing number of cancer cases worldwide is expected to boost the market growth, as AGEs significantly increase the level of inflammation in the body which has long been associated with the development of cancer. For instance, according to the National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer were diagnosed in the U.S., with around 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024 in the U.S.
Similarly, according to the American Cancer Society, 2015, an estimated 4.3 million new cancer cases and over 2.8 million cancer deaths were recorded in China, with lung cancer being the most common and the leading cause of cancer death.
Advanced Glycation End Products Market Report Coverage
||Market Size in 2020:
||US$ 1,368.5 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 2,130.1 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Type: Non-fluorescent AGEs, Fluorescent AGEs.
- By Application: Diabetic Complications, Cancer, Bone Diseases, Neurodegenerative Diseases, Others.
- By End User: Hospitals, Specialty Clinics, Homecare Settings.
Allergan Plc, Estée Lauder Companies, Shiseido Company, Beiersdorf AG, L'Oréal S.A, NuFACE, Ostium Cosmetics, PhotoMedex, Inc, Alma Laser, and Rodan & Fields, LLC
- Increasing product approvals and launches
- Increasing number of aesthetic procedures
- Increasing collaborations, acquisitions, and partnerships
|Restraints & Challenges:
- High cost of aesthetic procedures
Figure 2. Global Advanced Glycation End Products Market Share (%), by Type, 2020
Increasing cases of neurodegenerative diseases is expected to drive the market growth over the forecast period
Increasing cases of neurodegenerative diseases such as Alzheimer’s, Parkinson’s diseases, and other are expected to drive the market growth over the forecast period, as AGEs are proteins and glycated after exposure to sugars that is contribute to the development of neurodegenerative diseases. For instance, according to the World Alzheimer Report 2015 published by Alzheimer’s Disease International (ADI), in 2015 the new dementia cases in the regions were 4.9 million (49.0%) in Asia, 2.5 million (25.0%) in Europe, 1.7 million (18.0%) in the Americas, and 0.8 million (8.0%) in Africa. Furthermore, according to the Parkinson's UK, in 2015 there were around 137,000 people suffered from Parkinson’s in the U.K.
Global Advanced Glycation End Products Market – Impact of Coronavirus (Covid-19) Pandemic
Advanced glycation products (AGEs) resulting from the fixing of sugars on proteins, create cross links which definitively reduce the elasticity of elastin used in the aesthetic procedures. The American Society of Plastic Surgeons has recommended to postpone all the elective or non-essential services due to which the number of aesthetic procedures such as chemical peel, botulinum toxin therapy, dermabrasion, and others have decreased hindering the advanced glycation end products market growth. According to the article published in the Aesthetic Journal on April 03, 2020, around 81% of clinics are closed and 67% are experiencing reduction in revenue due to the COVID-19 lockdown in London.
Furthermore, several skincare and cosmetic companies are observing a decline in sales due to the COVID-19 pandemic. For instance, on May 12, 2020, Shiseido Company, a Japan-based multinational personal care company, released its financial statement for the first quarter of 2020 reporting a 14.6% and 19.2% year-on-year net sales decline in the American and Asia Pacific business, respectively.
Advanced Glycation End Products Market Restraint
High cost of aesthetic procedures is expected to hinder the market growth over the forecast period. According to the American Society of Plastic Surgeons, the average cost of botox treatment is US$ 397 in the U.S. while a single session of microdermabrasion costs around US$ 131 and the cost of chemical peel is around US$ 669.
Major players operating in the global advanced glycation end products market include Allergan Plc, Estée Lauder Companies, Shiseido Company, Beiersdorf AG, L'Oréal S.A, NuFACE, Ostium Cosmetics, PhotoMedex, Inc, Alma Laser, Rodan & Fields, LLC, and others.